Clinical trials: Brain Diseases, Metabolic
Phenylketonuria (PKU)
PANDA: PKU Amino Acid Evaluation
Phenylketonuria (PKU) is a rare inherited metabolic disorder, where subjects are born with a genetic deficiency in the phenylalanine hydroxylase enzyme (PAH), which leaves them unable to convert Phenylalanine (Phe) into Tyrosine…
- Trial name
- PANDA (NCT04086511)
- Where
- 2 sites in Belgium, United Kingdom
- Volunteers
- 37 people
- Sponsor
- Nutricia Research
Ischemic Stroke, Diabete Mellitus
DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes
Post-stroke cognitive impairment (PSCI) increases the risk of disability and mortality in stroke patients, thereby exacerbating the disease burden of stroke.
- Trial name
- NCT07241897
- Testing
- Sentagliptin Phosphate - single dose
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Overweight, Obesity
Brain's Response to Chocolate
The purpose of this study is to test how the brain responds when individuals eat enjoyable foods such as chocolate. Eating certain foods can make one want to keep eating even when feeling full, caused by dopamine in the brain.
- Trial name
- NCT03364413
- Testing
- Chocolate
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- USDA Grand Forks Human Nutrition Research Center
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
A Phase 2b Study of Zagociguat in Patients With MELAS
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs.
- Trial name
- PRIZM (NCT06402123)
- Testing
- zagociguat 15mg, zagociguat 30mg
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 43 people
- Sponsor
- Tisento Therapeutics
Friedreich Ataxia, Cardiomyopathy, Secondary
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy.
- Trial name
- NCT05445323
- Testing
- Low dose LX2006, Mid Dose LX2006, High Dose LX2006
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Lexeo Therapeutics
Fabry Disease
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
Evaluate the safety and efficacy of Fabagal® developed by ISU ABXIS Co., Ltd., which has similar efficacy to active comparator (Agalsidase beta).
- Trial name
- NCT06081062
- Testing
- Fabagal® (Agalsidase beta), Active comparator (Agalsidase beta)
- Where
- 3 sites in Philippines, South Korea
- Volunteers
- 24 people
- Sponsor
- ISU Abxis Co., Ltd.
Gangliosidoses, GM2, Sandhoff Disease
Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)
The objectives of this clinical trial are to assess the safety and tolerability, as well as efficacy, of a stepwise dosing regimen of pyrimethamine, starting at 25 mg/day, given as a single dose daily for 4 weeks in patients…
- Conditions
- Gangliosidoses, GM2, Sandhoff Disease, Tay-Sachs Disease
- Trial name
- NCT01102686
- Testing
- Pyrimethamine, Leucovorin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Gaucher Disease Type I
A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
This is a prospective single-center, open, single-arm, single-dose intravenous infusion study to evaluate the safety and initial efficacy, pharmacodynamic characteristics, immunogenicity, biodistribution, and viral shedding of…
- Trial name
- LY-M001 (NCT06162338)
- Testing
- LY-M001 Injection
- Where
- China
- Volunteers
- 3 people
- Sponsor
- He Huang
Pompe Disease (Late-onset)
Pompe Gene Therapy- Screening for Eligibility
The purpose of this study is to determine eligibility for the future clinical trial of gene therapy in adults with late-onset Pompe disease.
- Trial name
- NCT03285126
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Duke University
Primary Progressive Aphasia
Communication Bridge Pilot Study
The aim of this study is to evaluate the effectiveness and feasibility of evidence-based interventions in individuals living with mild to moderate primary progressive aphasia (PPA) that address communication-focused outcomes.
- Trial name
- CB3_1 (NCT06211374)
- Testing
- Communication Bridge
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Schizophrenia
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical…
- Trial name
- NCT02237417
- Testing
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Utah
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Hepatic Encephalopathy, Cirrhosis
iPod Games in Hepatic Encephalopathy
To see if using ipod games can improve mental functioning
- Trial name
- NCT02154282
- Testing
- ipod games
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Phenylketonuria (PKU)
PKU EASY Microtabs Plus - Acceptability and Tolerance
PEMP-AT is a prospective, single-arm, open-label, 1-week acceptability study to evaluate PKU EASY Microtabs Plus for the dietary management of participants with phenylketonuria (PKU).
- Trial name
- PEMP-AT (NCT06694662)
- Testing
- PKU EASY Microtabs Plus
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Galen Limited
Blood Pressure, Depression
Essential Hypotension and Allostasis Registry
The essential arterial hypotension and allostasis registry is a prospective, observational research that has the purpose of demonstrating that essential blood pressure (BP) disorders and the associated comorbidities are a result…
- Conditions
- Blood Pressure, Depression, Panic Attack, Fibromyalgia
- Trial name
- ESSENTIAL (NCT02018497)
- Where
- Colombia
- Volunteers
- 5,000 people
- Sponsor
- CES University
Semantic Dementia
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology…
- Trial name
- Veri-T-001 (NCT05184569)
- Testing
- Verdiperstat
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Peter Ljubenkov, MD
Malnutrition, Nutrition Poor
Extending the Validation of SCREEN to Persons Living With Dementia or in Retirement Homes
Older adults (≥ 55 years) who do not eat enough nutritious food are at risk of malnutrition. Malnutrition can lead to frailty, hospitalization, poor quality of life, and death.
- Conditions
- Malnutrition, Nutrition Poor, Dementia
- Trial name
- SCREEN (NCT04675229)
- Where
- Canada
- Volunteers
- 326 people
- Sponsor
- University of Waterloo
Acromegaly
Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788
A phase 1 healthy volunteer study to assess the excretion and metabolism as well as the absolute bioavailability of oral ONO-5788.
- Trial name
- ONO-5788-02 (NCT03849872)
- Testing
- ONO-5788, [14C]-ONO-5788
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Pompe's Disease
Feasability and Interest of Screening for Infantile Pompe's Diseases at Birth
Given the 100 fold increase of the incidence of Pompe's disease in Western French Guiana, the objective of the present study is to implement systematic screening in newborns in French Guiana in order to start treatment before the…
- Trial name
- DEPIPOMP1 (NCT02904395)
- Testing
- observational (no intervention)
- Volunteers
- 3,413 people
- Sponsor
- Centre Hospitalier de Cayenne
Parkinson Disease, Lewy Body Dementia
Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones
Small exploratory open-label pilot study to assess supplementation of a ketone ester (KetoneAid) as a potential therapy for persons with Parkinson disease (PD), Parkinson Disease Dementia/Lewy Body Dementia (PDD/LBD), and healthy…
- Conditions
- Parkinson Disease, Lewy Body Dementia, Parkinson Disease Dementia
- Trial name
- NCT05778695
- Testing
- Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Michigan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.